Compounded with
Semaglutide
Not verified in the bound record.
Tirzepatide
Not verified in the bound record.
Product evidence does not establish current availability.
Pharmacy evidence record · researched 2026-08-20
Healthy Choice Compounding Pharmacy, LLC
Not verified in the bound record.
Not verified in the bound record.
Product evidence does not establish current availability.
Regulatory compliance
A pathway label describes which federal rules apply — it is not a quality claim.
Section 503A
FDA evaluated products against section 503A and stated that some failed its conditions. This records the statutory pathway context, not FDA registration or a claim of blanket 503A compliance.
Section 503B
No exact current FDA outsourcing-facility registration was verified.
Telehealth providers
Clinic Scout links a provider only when an explicit source names the relationship.
Regulatory history
The exact FDA untitled letter and its referenced Form FDA 483 were verified. State-board action history and later closeout status were not exhaustively verified.
U.S. Food and Drug Administration · 2020-09-24
FDA issued a Form 483 after a September 2020 inspection. A Form 483 lists inspectional observations and is not itself a final agency determination.
issuedU.S. Food and Drug Administration · 2022-07-15
FDA stated that some products failed section 503A conditions and described insanitary-condition and strength/labeling concerns. This was an untitled letter, not a warning letter.
issuedNo Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.
What this record verifies for you
Each line traces to a citation in the source list below — read the exact captured wording before relying on it.
No superiority claim is made for review volume, ratings, or patient sentiment.
From September 17, 2020, to September 24, 2020, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Healthy Choice Compounding Pharmacy, located at 250 Clearbrook Rd, Elmsford, NY 10523.
FDA issued a Form FDA 483 to your firm on September 24, 2020.
During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA.
The FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA.
GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 4 dated first-party or regulator citation(s), 2 regulatory/action record(s), and 9 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.
Weekly price watch
One useful comparison each week. No spam, no sold lists, and you can unsubscribe anytime.